在多发性硬化症的III期临床试验中的并发症,安全性和持续性
Amber Salter1, Samantha Lancia2, Kaarina Kowalec3,4
1Section on Statistical Planning and Analysis, Neurology, UT Southwestern, Dallas, Texas, USA amber.salter@utsouthwestern.edu.
Journal of neurology, neurosurgery, and psychiatry
|May 24, 2025
概括
在多发性硬化症 (MS) 中,较高的并发症负担增加了不良事件的风险和疾病修饰疗法 (DMT) 的早期中止. 这凸显了管理伴随性疾病对MS治疗安全性和持续性的重要性.
科学领域:
- 神经学 神经学
- 临床药理学 临床药理学
- 流行病学 流行病学
背景情况:
- 伴随性疾病与多发性硬化症 (MS) 疾病修饰疗法 (DMT) 的持续性降低有关.
- 关于DMT治疗多发性硬化症患者的并发症和安全结果之间的关联存在有限的数据.
研究的目的:
- 评估伴随性疾病和安全结果之间的关联.
- 评估并发症对DMT在MS中的持续性影响.
主要方法:
- 从17个MS DMT临床试验的III期MS DMT临床试验中对个体参与者数据进行了两阶段的元分析.
- 检查了个别的并发症和并发症负担 (多达15种并发症的总和).
- 评估安全结果,包括不良事件 (AE) 如感染,自身免疫性疾病,癌症,过氨基酶升高,淋巴缺血症和早期试验中止.
主要成果:
- 包括16,794名MS参与者;64%的患者经历了2年多的副作用,主要是感染.
- 增加的并发症负担与较高的副作用率和早期试验中止相关.
- 精神疾病与试验中止特别相关.
结论:
- 在MS临床试验中,更高的并发症负担与增加的安全风险和早期停止DMT有关.
- 伴随性疾病在MS患者的DMT安全性和持续性方面发挥着重要作用.
关键词:
多发性硬化 多发性硬化相关概念视频
Clinical Trials
10.2K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
10.2K
Clinical Trials: Overview
4.6K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.6K
Drug Administration and Therapy Phases: Overview
1.3K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.3K
Bioavailability Study Design: Single Versus Multiple Dose Studies
217
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
217
Bioavailability Study Design: Healthy Subjects Versus Patients
144
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
144
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
233
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
233


